Joanna Hucz‐Kalitowska

Celon Pharma (Poland) — Poland

Medicine · Health Sciences

5h-index95citations15works1.32yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cytokine Signaling Pathways and Interactions(4), Fibroblast Growth Factor Research(3), Phosphodiesterase function and regulation(3), Cancer, Hypoxia, and Metabolism(2), PI3K/AKT/mTOR signaling in cancer(2)

Publications15 total

Abstract 3184: Development of an innovative bifunctional CPL976-MMAE conjugate based on a bispecific anti-PD-L1/ant-AXL antibody with a dual mechanism of action
Cancer Research·2024· 1 cited
Abstract 5084: A first-in-class bispecific antibody CPL976 with a dual PD-L1/AXL mechanism of action that promotes common biological antitumor effects in <i>in vitro</i> and <i>in vivo</i> models
Cancer Research·2024
Preclinical characterization of CPL304110 as a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3 for gastric, bladder, and squamous cell lung cancer
Frontiers in Oncology·2024· 3 citedOpen Access
A PDE10A inhibitor CPL500036 is a novel agent modulating striatal function devoid of most neuroleptic side-effects
Frontiers in Pharmacology·2022· 7 citedOpen Access
Design, Synthesis, and Development of pyrazolo[1,5-a]pyrimidine Derivatives as a Novel Series of Selective PI3Kδ Inhibitors: Part I—Indole Derivatives
Pharmaceuticals·2022· 4 citedOpen Access
CPL207280, a Novel G Protein–Coupled Receptor 40/Free Fatty Acid Receptor 1–Specific Agonist, Shows a Favorable Safety Profile and Exerts Antidiabetic Effects in Type 2 Diabetic Animals
Molecular Pharmacology·2021· 12 citedOpen Access
A novel JAK/ROCK inhibitor, CPL409116, demonstrates potent efficacy in the mouse model of systemic lupus erythematosus
Journal of Pharmacological Sciences·2021· 14 citedOpen Access
Discovery and optimization of novel pyrazole-benzimidazole CPL304110, as a potent and selective inhibitor of fibroblast growth factor receptors FGFR (1–3)
European Journal of Medicinal Chemistry·2020· 45 citedOpen Access
550P Preclinical characterization of CPL304110 as a potential selective inhibitor of fibroblast growth factors 1/2/3 in solid cancers
Annals of Oncology·2020· 2 cited
Preclinical characterization of CPL302-253, a selective inhibitor of PI3Kδ, as the candidate for the inhalatory treatment and prevention of Asthma
PLoS ONE·2020· 6 citedOpen Access
CPL-500-036-02 – novel and highly bioavailable PDE10A inhibitor activates cyclic nucleotides depending signaling in rat striatum
European Neuropsychopharmacology·2019
Pharmacokinetics of selective PI3Kδ inhibitors after intratracheal instillation in mice
2015· 1 cited
Preclinical characterization of CPL-302-201, a novel, highly potent and selective PI3Kδ inhibitor for the treatment of inflammatory disorders
2014
Therapeutic potential of CPL-407-105 – Novel potent JAK/STAT pathway inhibitor for the treatment of asthma
2014
P1‐024: CHARACTERIZATION OF A NOVEL GROUP OF PHOSPHODIESTERASE 9A INHIBITORS AS PUTATIVE THERAPEUTICS FOR COGNITIVE DYSFUNCTION
Alzheimer s & Dementia·2014Open Access

Frequent Co-authors

Maciej Wieczorek(14), Krzysztof Dubiel(10), Jerzy Pieczykolan(9), Daria Zdżalik-Bielecka(6), Aleksandra Stańczak(6), Monika Lamparska‐Przybysz(6), Paweł Gunerka(6), Monika Skupińska(6), Delfina Popiel(5), Paulina Seweryna Stańczak(4), Anna Bujak(4), Mikołaj Matłoka(4), Damian Smuga(4), Marcin Zagozda(4), Abdellah Yamani(3), Karolina Dzwonek(3), Sylwia Janowska(3), Krzysztof Mulewski(3), Barbara Dymek(3), Maciej Dziachan(3)